Thomas G. Wiggans, Director at Jasper Therapeutics, Inc. (JSPR), bought 41,000 shares at $2.43 ($100K) on 2025-09-22, disclosed to the SEC on 2025-09-24.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| Filing → |
| JSPR | BUY | 2023-11-20 | $18K | — | Filing → |
| PRDS | BUY | 2022-12-07 | $14K | — | Filing → |
| PRDS | BUY | 2022-12-05 | $39K | — | Filing → |